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ABSTRACT 45 
 46 
Background: Data from rodent models suggest that a subpopulation of CD4+ T-cells, 47 
characterised by the constitutive expression of CD25, play a key role in regulating many 48 
immune responses. Human CD4+CD25+ T-cells also appear to possess a regulatory 49 
function but their role in infections is not fully defined. 50 
Objectives: To explore the possibility of a role for CD4+CD25+ T-cells in controlling 51 
immunity to hepatitis C virus (HCV). We hypothesised that CD4+CD25+ T-cells may 52 
account for the paucity of immune responses measurable in chronically viraemic patients 53 
by suppressing the immune responses to HCV antigens. 54 
Methods: We compared the responses of peripheral blood mononuclear cells (PBMC) to 55 
3 different recombinant HCV antigens before and after depletion of CD25+ cells in 15 56 
chronically viraemic patients, 14 non-viraemic HCV antibody positive subjects, and 14 57 
healthy controls. We also tested the ability of CD4+CD25+ T-cells purified from human 58 
leukocyte antigens (HLA)-matched viraemic or non-viraemic blood to suppress the 59 
responses of HCV-epitope specific T-cell clones.  60 
Results: To our surprise, depletion of peripheral blood CD25+ cells led to a pronounced 61 
increase in proliferation of and interferon-γ production by PBMC only in non-viraemic 62 
patients. Furthermore, the CD4+CD25+ T-cells purified from HLA-matched non-viraemic 63 
blood (in contrast to CD4+CD25+ T-cells isolated from chronically viraemic blood) 64 
inhibited the responses of HCV-epitope specific T-cell clones.  65 
Conclusion: HCV-specific CD4+CD25+ regulatory T-cells appear to accompany 66 
successful viral clearance. 67 
Clinical Implication: Our findings offer an insight into a possible strategy utilised by 68 
hosts to control cross-reactivity and immunopathology following viral clearance. 69 
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Capsule Summary:  70 
Our study provides the first persuasive evidence of the development of antigen-specific Tregs in 71 
the course of normal immune responses in humans and offers an insight into a possible 72 
strategy utilised by hosts to control cross-reactive immunopathology. 73 
 74 
Key words: Hepatitis C infection, regulatory T-cells, autoimmunity, viral clearance, viral 75 
persistence 76 
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INTRODUCTION 81 
 82 
In rodent models, CD4+CD25+ regulatory T-cells (Tregs) has been shown to play a 83 
central role in the regulation of immune responses 1, 2. Tregs are potent suppressors of 84 
CD4+ and CD8+ T-cells in vitro and in vivo. We and others have reported that 85 
CD4+CD25+ T-cells in humans share many of the characteristics of their murine 86 
counterparts 3-10 .These Tregs appear to be a part of the normal repertoire of peripheral 87 
CD4+ T-cells, but their function in health and disease remains to be fully defined in man. 88 
Tregs have been implicated in controlling immune responses to various pathogens 11, but 89 
neither the origin nor the physiological function of these Tregs has been fully elucidated. 90 
 91 
HCV causes chronic infection in 80% of infected individuals 12 and is a major cause of 92 
morbidity and mortality worldwide. Following exposure to HCV, a minority of infected 93 
individuals successfully eradicate the virus either spontaneously or following treatment 94 
with interferon and ribavirin 13. The outcome of a viral infection is determined by the 95 
interplay of viral factors and host immune responses. In general, the generation of virus-96 
specific cytotoxic T-lymphocytes (CTL) during the initial phase of the infection is crucial 97 
to the subsequent control of the infection 14, 15. The maintenance of virus-specific CTL-98 
responses, however, depends on antigen-specific CD4+ T-helper cell activity 16. Indeed, 99 
the ability to mount a strong and sustained anti-viral Th1 response was associated with 100 
subsequent viral clearance while failure to develop or sustain a HCV-specific CD4+ T-cell 101 
response was associated with chronic infection 17. The discovery of a naturally-occurring 102 
Tregs raised the possibility that these cells may be subverted by the invading virus to 103 
inhibit anti-viral responses. In this study, we tested this hypothesis by investigating the 104 
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anti-viral responses in patients with persistent viraemia and individuals who have 105 
successfully eradicated the virus.  106 
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METHODS 107 
 108 
Study population 109 
Patients were diagnosed with past or present HCV infection by clinical history and the 110 
presence of anti-HCV antibodies. Chronic infection was diagnosed by the persistence of 111 
viral RNA (measured by nested polymerase chain reaction (PCR)) in serum at least 6 112 
months after exposure. A cleared infection was diagnosed by at least 3 negative HCV 113 
PCRs each separated by 6-12 months and normal liver function tests. 8 out of 14 non-114 
viraemic patients had previously received interferon (IFN)-α. The human leukocyte 115 
antigen (HLA) typing was performed using allele-specific primer-PCR. Ethical 116 
committee approvals (St Mary's Hospital NHS Trust and Cardifff and Vale NHS Trust, 117 
United Kingdom (UK)) were granted. Clinical characteristics of the patients are 118 
summarized in table E1 in the online repository. 119 
 120 
Culture Media and reagents  121 
RPMI-1640 medium supplemented with L-glutamine, penicillin/streptomycin, 122 
amphotericin, all from Gibco BRL, Paisley, UK, and gentamicin (Sigma, Poole, UK), 123 
with 10% added human AB serum (Harlan Sera-Lab, Loughborough, UK) was used. All 124 
cells were incubated at 37 oC in a humidified atmosphere with 95% air and 5% CO2.  125 
 126 
HCV Antigens 127 
The peptides were synthesized commercially (ECHAZ micro collections, Tubingen, 128 
Germany) according to the sequence of viral genotype 1a based on Simmond's 129 
classification (epitopes 1.2: core 31-45, 2.2: core 141-155). HCV recombinant viral 130 
proteins were a kind gift from Chiron Corporation, California [core protein: c22-3 (2-131 
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120); non-structural proteins: c200 (NS3/4 1192-1931); NS5 (2054-2995)]. Tuberculin 132 
purified protein derivative (Hammersmith Hospitals NHS Trust, London, UK) and tetanus 133 
toxoid (Evans vaccines, UK) were used as control antigens. 134 
 135 
Antibodies  136 
FITC-conjugated anti-CD4 (Becton Dickinson, Oxford, UK), PE-conjugated anti-CD25 137 
(Caltag, Silverstone, UK), FITC-conjugated anti-Foxp3 (ebioscience), PerCP-Cy5.5-138 
conjugated anti-CD4 (Pharmingen), isotype controls antibodies (Caltag) were used in 139 
flow cytometry. Antibodies from clones 43-11, 9D7 (Immunokontact, Witney, UK), 140 
9016.2 (R&D, Abingdon, UK) were used as capture antibodies for detection of ΙFN-γ , 141 
interleukin (IL)-10, transforming growth factor (TGF)-β in enzyme-linked 142 
immunosorbent assays (ELISA) respectively. The corresponding detection antibodies 143 
used were 45-15 (Immunokontact), 12G8 (Becton Dickinson), anti-TGF-β chicken Ig 144 
(R&D). The cytokine standards used were recombinant human IFN-γ (Biosource, 145 
Nivelles, Belgium), IL-10 (Firstlink, Birmingham, UK) and TGF-β (R&D). 146 
 147 
Proliferation assays 148 
PBMC were isolated from peripheral blood by centrifugation over Lymphoprep 149 
(Nygaard, Birmingham, UK). CD25+ cells were removed from PBMC by immuno-150 
magnetic depletion with CD25 Dynabeads (Dynal, Wirral, UK) according to 151 
manufacturer’s protocol. Triplicates of 2x105 PBMC or CD25+ cell-depleted PBMC per 152 
well were incubated in 96-well round-bottomed plates. 10 µg/ml of antigen was added to 153 
the test wells. After 6 days, 75 µl of supernatant was collected for measurement of 154 
cytokine production. To the remaining culture, medium containing 0.5 µCi of  3H-155 
thymidine  (Amersham Life Sciences, Amersham, UK) was added, proliferation was 156 
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measured by incorporation of 3H-thymidine using a β-counter after 12-16 hours. The 157 
stimulation index (SI) was calculated by counts per minute (cpm) with antigen / cpm 158 
without antigen. Response to phytohaemagglutinin (PHA, 2 µg/ml, Sigma), measured at 159 
day 3, was used as positive controls. 160 
 161 
Measurement of cytokine production with ELISA 162 
 163 
This was carried out as described previously 3. Cytokine concentrations and limits of 164 
detection were calculated using the standard curves derived from the cytokine standards. 165 
The detection limits for IFN-γ, IL-10, and TGF-β were 2.5-20, 4-40 and 15-65 pg/ml 166 
respectively. SI were calculated as for proliferation assays. If the calculated cytokine 167 
concentrations were below detection limits, the value equate to the limit of detection of 168 
that assay was assigned for the purpose of SI calculation. 169 
 170 
Purification of CD4+CD25+ and CD4+CD25- T-cells 171 
This was carried out as described previously 3. The purity of CD4+CD25- cells was 85-172 
90%, and CD4+CD25+ cells was 90-95%, as measured by flow cytometry. The 173 
contamination of CD4+CD25- cells consisted of mostly CD4+CD25lo T-cells. Depletion of 174 
these CD4+CD25lo cells made no difference to the functional responses of the 175 
CD4+CD25- cell population (Lechler R, unpublished observation).  176 
 177 
Generation of HLA-DR11-restricted HCV-epitope specific T-cell clones 178 
PBMC from a non-viraemic HLA-DR11+ subject were used to generate short term T-cell 179 
lines to peptide 1.2 or 2.2 as described previously 18. The T-cell lines were plated out at 180 
0.3 cells per well in the presence of 105 irradiated autologous PBMC and PHA. Cultures 181 
were fed with fresh medium containing 50 IU/ml of recombinant IL-2 every 3-4 days. 182 
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Cells from growth-positive cell cultures were tested in a 3H-thymidine proliferation assay 183 
after 10-12 days to identify antigen-specific clones. To assay the clones, 5 x 103 T-cells 184 
were cultured with 5 x 104 irradiated HLA-DR11+ PBMC and 10 µg/ml of peptide for 48 185 
hours. For inhibition experiments, CD4+CD25+ or CD4+CD25- T-cells were added at a 186 
ratio of 2:1 (i.e. 104 / well) to the culture. 187 
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RESULTS  188 
 189 
Responses to recombinant HCV antigens were more readily detectable in non-190 
viraemic patients when compared to chronically infected patients  191 
We compared the proliferative responses in 15 chronically infected subjects, 14 non-192 
viraemic HCV antibody positive subjects, and 14 healthy controls to recombinant viral 193 
proteins [c22-3, c200; and NS5] (Fig. 1A). Both groups of HCV-exposed subjects 194 
contained some responders [defined as a SI > 3] to the c22-3 protein. However there was 195 
an increased response in the non-viraemic group to both c200 (7 out of 14 (non-viraemic 196 
group) vs. 1 out of 15 (viraemic group) and NS5 (2 out of 10 (non-viraemic group) vs. 0 197 
out of 12 (viraemic group)) antigens. The responses to control antigens were similar 198 
indicating that non-specific immunosuppression did not account for the poor anti-viral 199 
responses in viraemic subjects (Fig. 1B). No positive response was detected to any of the 200 
viral antigens among unexposed healthy individuals (p<0.0006, HCV-exposed vs. 201 
unexposed), suggesting that these anti-viral responses were induced following antigen 202 
exposure and were biologically relevant. 203 
 204 
Depletion of peripheral blood CD25+ cells enhanced the proliferative responses to 205 
HCV antigens in non-viraemic, but not chronically infected patients  206 
The reason for the paucity of anti-viral responses is unclear. We have shown that HCV 207 
epitope-specific CD4+ T-cell responses can be clearly demonstrated if the T-cells are first 208 
exposed in vitro to exogenous IL-2 18, 19. PBMC from these same individuals usually 209 
failed to respond in standard 5-day proliferation assays to these epitopes without 210 
exogenous IL-2 (Godkin A, unpublished data). We have also shown that the addition of 211 
IL-2 in vitro abrogates the suppressive function of Tregs in humans 3. Furthermore, Tregs 212 
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can be induced in the context of a chronic antigenic burden (e.g. allografts) and transfer 213 
of these cells to naive recipients confers tolerance to the same alloantigens 20. Thus, it is 214 
possible that the chronic presence of HCV antigens may also induce HCV-specific Tregs. 215 
To test this hypothesis, we compared the effects of CD25+ cells depletion on anti-HCV 216 
responses in viraemic and non-viraemic individuals. Proliferative responses to the HCV 217 
antigens were measured before and after depletion of CD25+ cells from PBMC; the recall 218 
antigens tuberculin purified protein derivative (PPD) and tetanus toxoid (TT) were used 219 
as controls. To our surprise, depletion of CD25+ cells had only minimal effect on the 220 
responses to HCV antigens in patients with chronic infection, but on the responses in non-221 
viraemic subjects it was striking. 10 individuals in the non-viraemic group (71%) showed 222 
an enhanced response (SI > 3 after depletion) to one or more HCV antigens. Of the total 223 
38 assays performed with viral antigens in the non-viraemic group, the SI increased in 224 
55% after depletion while just 5% decreased (Fig. 2A). In the assays that showed an 225 
enhanced response, 32% had a SI < 3 before depletion. Hence, the depletion of the CD25+ 226 
cells unmasked anti-HCV responses which were previously not apparent among non-227 
viraemic subjects. In contrast, only 3 viraemic subjects (19%) had an enhanced response 228 
to one or more viral antigens after depletion. In this group, merely 17% of the total 41 229 
assays revealed an increase and 10% a decrease in the SI after depletion (Fig. 2B). Thus, 230 
our initial hypothesis was not supported by the experimental findings since depletion of 231 
CD25+ cells had an insignificant effect in chronically infected patients. Interestingly, in 232 
the non-viraemic group, among the assays which demonstrated an initial positive 233 
response (n=13), the SI was higher in 11 (85%) after depletion of CD25+ cells. In 234 
contrast, among the positive initial responses in viraemic patients (n=4), only 1 had a 235 
higher SI post-depletion, raising the possibility that the CD25+ cells in these patients were 236 
activated viral antigen-specific cells rather than regulatory cells. 237 
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 238 
An alternative, more stringent, definition of an increased response is a greater than two-239 
fold increase in the SI after depletion. If this definition was used, similar result was 240 
obtained in that CD25+ cell-depletion had a much more pronounced effect on non-241 
viraemic subjects. 7 individuals (50%) showed a two-fold increase in response to one or 242 
more HCV proteins after depleting CD25+ cells. Of the total 38 assays performed with 243 
HCV antigens in the non-viraemic group, a two-fold increase in the SI was observed in 13 244 
(34.2%) after depletion whilst just 1 (2.6%) showed a two-fold decrease in the SI. In 245 
contrast, only 2 viraemic subjects (13%) had an increased response to one or more HCV 246 
antigens after depletion. 3 out of the total 41 (7.3%) assays revealed a two-fold increase 247 
in response and 3 assays (7.3%) showed a two-fold decrease. Depletion of CD25+ cells 248 
had no effect on unexposed healthy controls. None of the 40 assays showed an increased 249 
response. In our patient or control groups, no significant difference was seen in the 250 
responses to the control antigens before and after depletion of CD25+ cells. (mean SI pre-251 
and post-depletion were 37 vs. 33 (viraemic,  p=0.52); 29 vs. 34 (non-viraemic, p=0.45); 252 
and 30 vs. 33 (unexposed, p=0.56)). Responses to PHA were enhanced following 253 
depletion of CD25+ cells in all subjects (data not shown). 254 
 255 
Depletion of peripheral blood CD4+CD25+ cells enhanced IFN-γ production to HCV 256 
antigens in non-viraemic subjects 257 
Following antigen stimulation, T-cells produce various cytokines that serve important 258 
effector functions. For instance, proinflammatory cytokines protect against viral infection 259 
whereas anti-inflammatory cytokines may facilitate viral persistence. In this study, we 260 
measured the production of IFN-γ, IL-10 and TGF-β in the culture supernatant using 261 
ELISA. PBMC from 5 viraemic and 2 non-viraemic subjects produced IFN-γ (defined as 262 
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SI>3) when stimulated with NS-5. There was no IFN-γ response to c22-3 or c200 in 263 
either viraemic or non-viraemic individuals. However, upon depletion of CD25+ cells, 7 264 
non-viraemic subjects produced IFN-γ in response c200 antigen (Fig. 3A). In contrast, 265 
only 1 viraemic patient showed a positive response following CD25+ cell-depletion. This 266 
observation further corroborates our finding on the effect of CD25+ cell-depletion on 267 
proliferative responses in HCV-exposed subjects. Another explanation for the paucity of 268 
anti-HCV responses in viraemic patients is the presence of regulatory cytokines such as 269 
IL-10 and TGF-β. In this study, none of the viraemic or non-viraemic subjects produced 270 
IL-10 to the 3 HCV antigens tested. Regarding TGF-β production, 1 viraemic patient and 271 
3 non-viraemic subjects produced TGF-β in response to c200 or NS5. However, 3 healthy 272 
volunteers also responded to c200 and another 3 responded to NS5 (data not shown). 273 
Finally, depletion of CD25+ cells has minimal impact on the production of IL-10 and 274 
TGF-β in either viraemic or non-viraemic subjects (data not shown). 275 
 276 
CD4+CD25+ cells from non-viraemic, but not chronically infected individuals 277 
suppress the proliferation of HCV-epitope specific T-cell clones 278 
Data from rodent models suggest that activation of Tregs via the TCR is antigen-specific 279 
1, 2
. For instance, in mice transgenic for a TCR specific for an ovalbumin peptide, Tregs 280 
can be activated by ovalbumin peptide presented by autologous antigen-presenting cells 281 
21
. Little is known in humans regarding the antigen-specificity of Tregs. Our data suggest 282 
that a population of Tregs is present within the peripheral blood CD25+ population in 283 
non-viraemic patients and regulate, to a degree, anti-HCV immune responses.  284 
 285 
We have previously demonstrated that the HCV epitopes 1.2 and 2.2 are recognised by all 286 
HLA-DR11+ non-viraemic individuals 18, 19. An HLA-DR11-restricted clone recognising 287 
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the epitope 1.2 was generated. Peripheral blood CD4+CD25+ or CD4+CD25- cells from an 288 
HLA-DR11+ non-viraemic subject were added to clone cell at a ratio of 2:1. Only the 289 
CD4+CD25+ cells reduced the proliferation of the clone (Fig. 4A). In contrast, no 290 
inhibition was seen when CD4+CD25+ cells from a HLA-DR11+ viraemic patient were 291 
used (Fig. 4B), consistent with the earlier observation that HCV-specific Tregs do not 292 
appear to be prominent in viraemic individuals. Similar results were obtained when a 293 
different clone specific for the viral epitope 2.2 was used (Fig. 4C&D). CD4+CD25+ cells 294 
from a healthy control had no effect on the proliferation by the T-cell clones (data not 295 
shown). Similar results were obtained when the experiments were repeated using 296 
CD4+CD25+ cells from another HLA-DR11+ non-viraemic subject and -DR11+ viraemic 297 
individual (data not shown). 298 
 299 
After the completion of these experiments, Foxp3 expression was identified as a more 300 
specific marker for Tregs than CD25, as CD25 is expressed also on recently activated T-301 
cells. Thus, it is possible that CD4+CD25+ cells from viraemic subjects contained mainly 302 
recently activated T-cells. However, of the viraemic / non-viraemic patients whom we 303 
have studied, the frequencies of Tregs as defined by CD4+CD25hiFoxp3+ expression 304 
among these subjects was similar (Fig. E1 in the online repository).  305 
 306 
Taken together, our data suggest that populations of Tregs are generated after viral 307 
clearance and that these regulatory cells can be activated by the same HCV epitopes 308 
which are thought to be important in viral clearance 18, 19.  309 
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DISCUSSION 310 
 311 
In this study, we showed that the responses to recombinant HCV antigens are more 312 
readily detectable in subjects who had eradicated the virus compared to those with 313 
persistent viraemia. The poor responses to HCV antigens in viraemic PBMC could not be 314 
reversed by depleting peripheral blood CD25+ cells. Instead, we found that Tregs with 315 
specificity for HCV antigens appear to be induced following viral clearance.  316 
 317 
The differential effect of CD25+ cell-depletion on the proliferative responses to the viral 318 
antigens among the viraemic and non-viraemic subjects was unlikely to be the result of a 319 
quantitative difference in the number of Tregs remaining following CD25+ cell-depletion, 320 
as this was typically less than 2%. The contaminating CD4+CD25+ cells were CD25lo, 321 
which do not possess regulatory function. Furthermore, the fraction of peripheral blood 322 
CD4+CD25+ T-cells was similar in all 3 study groups and was comparable to our previous 323 
study in healthy human subjects 3 (Fig. E2 in the online repository). In addition, we 324 
showed that the frequency of CD4+CD25+Foxp3+ cells in viraemic and non-viraemic 325 
individuals were similar and that CD4+CD25+ cells from both viraemic and non-viraemic 326 
subjects inhibited polyclonal responses of CD4+CD25- cells. These observations indicate 327 
that there is no significant global defect of Tregs in viraemic patients.   328 
 329 
In this study, the enhancement of anti-viral antigen responses was detected in non-330 
viraemic individuals who had received IFN-α treatment (6 out of 8) as well as those who 331 
eliminated the virus spontaneously (4 out of 6). The number of patients included in this 332 
study, however, does not have the power to allow any conclusion to be drawn concerning 333 
the effects of treatment on these analyses. Since all the viraemic patients had received 334 
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IFN-α treatment, the lack of enhancing effect on the anti-HCV antigen response 335 
following depletion of CD25+ cells in this group of patient argue against a substantial role 336 
for IFN-α in the development of these regulatory cells.   337 
 338 
Little is known regarding the antigen-specificity of Tregs. It has been suggested that 339 
Tregs are specific for self-antigens 1, 22 but evidence is accumulating that these cells might 340 
also recognize non-self antigens 11, 23. Our data suggest that a population of Tregs capable 341 
of regulating anti-HCV responses could be found following successful eradication of the 342 
virus. Furthermore, these Tregs were activated by the same viral epitopes that are thought 343 
to be important in viral clearance. 344 
 345 
The origin of these Tregs with apparent HCV specificity in the non-viraemic patients 346 
remains to be elucidated but two possibilities exist. First, this may represent cross-347 
reactivity by self-peptide-specific T-cells on HCV-derived epitopes. It has been reported 348 
that both human and murine Treg populations have a diverse TCR repertoire 23, 24. On this 349 
basis, it is plausible that the small fraction of Tregs that can cross-reactively recognise an 350 
exogenous antigen such as HCV peptide, can clonally expand during the course of an 351 
anti-viral immune response. The alternative possibility is that these cells arise de novo 352 
from uncommitted T-cells during an anti-viral immune response, or arise by conversion 353 
of effector T cells into Tregs 25. Although it is clear that the majority of Tregs derive from 354 
the thymus 21, 26, Tregs can also be generated from uncommitted peripheral T-cells 23, 27. 355 
Consistently, it has been shown that antigen-related expansions within certain TCR-Vβ 356 
families were associated with parallel increases of CD4+CD45RO+CD25hiFoxp3+ 357 
regulatory T-cells with the same Vβ usage 28. 358 
 359 
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Viral infections have been linked with triggering diverse autoimmune conditions 29. This 360 
may result from molecular mimicry between a viral and self-epitope 30. Thus, a possible 361 
role for Tregs maybe to prevent pathogen-specific T-cells triggering autoimmune disease 362 
or causing excessive tissue damage following viral clearance. Consistent with this 363 
hypothesis, Boyer et al reported that the Tregs deficiency in patients with chronic HCV 364 
infection is associated with mixed cryoglobulinaemia 31. Similarly, reduction of tissue-365 
damaging immunopathology by Tregs have also been demonstrated in herpes simplex 366 
viral infection 32, as well as some parasitic and fungal infections 33.  367 
 368 
Recent reports have focused on the role of Tregs in chronic HCV infection. These Tregs 369 
derived from chronically infected subjects suppressed CD8+ T-cells specific for HCV as 370 
well as other viruses (e.g. EBV, influenza) 34-37. We focused on Tregs derived from both 371 
chronically infected and non-viraemic HCV-exposed subjects, and found Tregs from non-372 
viraemic subjects specifically suppressed anti-HCV CD4+ T-cells. One unifying 373 
hypothesis that may explain these observations is that in patients who eradicated the 374 
virus, effective CD4+ and CD8+ anti-HCV responses were elicited, which was 375 
accompanied by the expansion of virus-specific Tregs in order to limit potential collateral 376 
damage. In viraemic patients, HCV-specific Tregs were not induced/expanded since there 377 
was no effective anti-viral response elicited. However, Tregs with other specificities may 378 
still be expanded/activated non-specifically in the context of a viral infection (e.g. via 379 
toll-like receptor ligand activity). Since activated Tregs can suppress non-specifically 1,2, 380 
this non-specific increase in Treg frequency/function may perpetuate viral persistence by 381 
preventing the development of an effective anti-HCV CD8+ T-cell response. Consistent 382 
with this hypothesis, Manigold et al recently reported that, in a chimpanzee model of 383 
HCV infection, CD4+CD25+Foxp3+ cells from both HCV-recovered and HCV-384 
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persistence chimpanzees can suppress HCV-specific T-cell responses. Interestingly, 385 
depletion of CD25+ cells from PBMC increased the number of HCV-specific IFN-386 
γ ELISPOTs most notably in those chimpanzees that had recovered from multiple 387 
sequential infections. In contrast, the increase in IFN-γ responses after depletion of CD25+ 388 
T-cells was significantly weaker in chimpanzees that had recovered from a single 389 
infection and in viraemic chimpanzees 38. Thus these observations strongly corroborate 390 
our findings. Another possible explanation for the discrepant results is that the 391 
CD4+CD25+ population may contain a mixture of recently activated as well as Tregs. 392 
Since our depletion protocol consistently depleted both CD4+CD25hi and CD4+CD25int 393 
populations, augmentation of responses to HCV antigens in viraemic patients by 394 
depletion of Tregs might be masked by the concomitant depletion of HCV-specific 395 
activated T-cells. Furthermore, heterogeneity of patient cohorts, infection history, co-396 
morbidity and different HCV antigens used may also contribute to the discrepancy in 397 
different studies. Finally, although we did not detect significant HCV-specific Tregs 398 
activity in viraemic patients, it is possible that HCV-specific Tregs were present within 399 
the liver as this study focused only on Tregs from peripheral blood. 400 
 401 
The paucity of anti-HCV responses in viraemic patients may reflect the presence of 402 
suppressive cytokines such as IL-10 or TGF-β. It was reported that both unstimulated and 403 
HCV antigen-induced IL-10 production by peripheral blood lymphocytes were increased 404 
in patients with chronic HCV infection 39. We also found that unstimulated PBMC from 405 
viraemic patients produced higher levels of IL-10 compared to healthy controls 406 
(mean=85.7, 50.8, 4.5 pg/ml for viraemic, non-viraemic and unexposed respectively, 407 
p=0.239 viraemic vs. non-viraemic, p=0.002, viraemic vs. unexposed and p=0.085 non-408 
viraemic vs. unexposed). However, stimulation with HCV antigens did not significantly 409 
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increase IL-10 production by PBMC from viraemic patients (mean=85.7 vs. 101.0 pg/ml, 410 
p=0.93; and no patient had a SI>3). Nevertheless, IL-10 production varied considerably 411 
between individual patients (4-254 pg/ml and 4-418 pg/ml, unstimulated and HCV 412 
antigen-stimulated samples respectively), it remains possible that IL-10 may contribute to 413 
suppress anti-HCV responses in some viraemic patients. Production of TGF-β was 414 
generally low and highly variable between individuals, but there was no difference 415 
between all 3 groups of subjects (data not shown). 416 
 417 
In conclusion, our data strongly suggest that the presence of HCV-specific Tregs 418 
accompany successful clearance of the virus. A plausible explanation is that antigen-419 
specific Tregs were induced in these patients in order to minimise the potential by-stander 420 
damage associated with a potent anti-viral T-cell response. To our knowledge, this is the 421 
first persuasive evidence of the development of antigen-specific Tregs in the course of normal 422 
immune responses in humans, a result that has now been corroborated in a chimpanzee 423 
model of HCV infection.424 
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Figure 1. Proliferative T-cell responses to HCV and control antigens. 2x105 PBMC 538 
per well from viraemic patients (designated PCR pos); non-viraemic individuals 539 
(designated PCR neg); and unexposed, healthy controls were stimulated with (A) viral 540 
antigens (B) control recall antigens. Proliferative responses are considered positive if the 541 
SI>3. 542 
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Figure 2. Proliferative responses to viral and control antigens in non-viraemic and viraemic subjects before and after depletion of CD25+ cells. (A) Of the 38 assays 543 
in the presence of HCV antigens performed in the non-viraemic group (n=14), the 21 assays which had a SI>3 either before or after the depletion are shown.  Similarly, all 544 
assays which had a SI>3 before or after depletion of CD25+ cells to control antigens are shown. (B) 41 assays were performed using HCV antigens in the chronically infected 545 
individuals (n=15), and of these 10 assays showed a SI>3 either before or after the depletion. Similarly, all assays which had a SI>3 before or after depletion of CD25+ cells 546 
to control antigens are shown. 547 
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 549 
Figure 3. Cytokine responses to HCV antigens before and after depletion of CD25+ 550 
T-cells. Cytokine production in supernatant from HCV c200-stimulated PBMC before 551 
and after CD25+ cell-depletion. Cytokines were measured with ELISA. Data were 552 
expressed as SI (i.e. concentration of cytokine with antigen / background cytokine 553 
production with no antigen).(A) IFN-γ, (B) IL-10, (C) TGF-β. Only the non-viremic 554 
group showed an increase in IFN-γ after CD25+ cell depletion.  555 
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 558 
Figure 4. The effect of CD4+CD25+ T-cells on proliferation of HCV epitope-specific clones. (A-D) 559 
5x103 cells of clone 1.2 (A, B) or clone 2.2 (C, D) were co-cultured with 104 CD4+CD25+ (designated 560 
“+p/25+”) or CD4+CD25- (designated “+p/25-“) T-cells from non-viraemic (A, C) or viraemic (B, D) blood 561 
in the presence of appropriate HCV peptides (10 µg/ml). Clones cells stimulated with (designated “+p”) or 562 
without (designated “none”) appropriate HCV peptides were used as positive and negative controls 563 
respectively. 5x104 irradiated HLA-DR11+ PBMC were used as accessory cells in all wells. Proliferation 564 
was measured after 2 days. (E-F). 104 CD4+CD25+ T-cells from non-viraemic (E) or viraemic (F) blood 565 
were co-cultured with 104 autologous CD4+CD25- T-cells in the presence of 5x104 irradiated autologous 566 
PBMC and PHA. Proliferation was measured after 72 hours. 567 
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Figure E1. (A) Percentage of CD4+CD25hi, CD4+CD25int and CD4+CD25- cells as a 572 
percentage of CD3+ cells. (B-D) Percentages of CD4+CD25hi gated cells (B), 573 
CD4+CD25int gated cells (C) and CD4+CD25- gated cells (D) that express Foxp3 and the 574 
mean fluorescent intensity (MFI) of Foxp3 expression. (E) There was no statistically 575 
significant difference in the percentages of CD3+CD4+Foxp3+ (right graph, p=0.16) and 576 
CD3+CD4+CD25hi (left graph, p=0.79) cells in viraemic and non-viraemic subjects. 577 
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 582 
Figure E2.(A) Percentages of CD4+CD25+ cells before and after CD25+ cell depletion 583 
from PBMC. ND denotes not done because insufficient numbers of PBMC or CD25-584 
depleted cells were obtained from the samples. (B) The mean percentage of CD4+CD25+ 585 
cells before and after CD25+ cell depletion in the 3 study groups. There was no statistical 586 
significant difference either before or after CD25+ cell depletion across all 3 groups. 587 
 588 
Viraemic  Non-viraemic  Healthy Controls 
 % of CD4+CD25+ 
cells 
  % of CD4+CD25+ 
cells 
  % of CD4+CD25+ 
cells 
   Before  After   Before  After   Before  After 
CV1 17.80 ND  NV1 13.35 ND  H1 16.33 0.61 
CV2 28.70 1.38  NV2 23.17 ND  H2 13.85 0.92 
CV3 12.52 0.11  NV3 15.83 1.59  H3 18.52 0.75 
CV4 19.81 1.51  NV4 22.33 0.77  H4 20.13 2.46 
CV5 17.42 0.18  NV5 19.45 0.86  H5 17.96 1.15 
CV6 24.21 3.39  NV6 16.27 1.23  H6 29.23 2.05 
CV7 13.48 3.55  NV7 21.08 1.88  H7 19.67 0.19 
CV8 15.97 ND  NV8 18.34 1.47  H8 17.34 1.56 
CV9 18.12 1.96  NV9 17.04 0.76  H9 20.25 0.32 
CV10 18.34 ND  NV10 25.28 1.18  H10 22.23 1.03 
CV11 20.30 0.86  NV11 24.98 1.03  H11 16.21 0.97 
CV12 22.13 1.32  NV12 19.22 1.97  H12 23.04 1.22 
CV13 14.40 1.04  NV13 18.59 1.55  H13 15.60 1.78 
CV14 ND ND  NV14 20.52 0.48  H14 15.09 1.35 
CV15 25.20 0.98         
